Martin William, Luís Catarina, Jungbluth Stefan, Slezak Monika, Verreck Frank A W, Spiegel Holger, Guzman Carlos A, Roldão António, Carrondo Manuel J T, Van der Ley Peter, Segalés Joaquim, Dockrell Hazel M, Ho Mei Mei, Pedersen Gabriel K, Lawrenz Maria, Olesen Ole F
European Vaccine Initiative (EVI), 69115 Heidelberg, Germany.
Biomedical Primate Research Centre (BPRC), 2288 GJ Rijswijk, The Netherlands.
Vaccines (Basel). 2024 Dec 22;12(12):1446. doi: 10.3390/vaccines12121446.
TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.
TRANSVAC是一项长期努力，旨在通过将欧洲各地的机构整合到一个单一的合作框架下，加速新型疫苗的开发。自2009年以来，该倡议为全球疫苗界提供了支持，包括为候选疫苗的开发和优化以及新佐剂、研究方案和技术的提供做出贡献。提供了科学服务以支持88个不同的疫苗开发项目，400名专业人员参加了关于各种疫苗相关主题的TRANSVAC培训活动。在此，我们回顾TRANSVAC联盟的成就，并分析欧洲学术和工业疫苗开发者的持续需求。研究结果突出了通过TRANSVAC等研究基础设施和其他机制在不同部门之间进行协调的好处，以应对当前和未来的全球卫生挑战，并确保欧洲疫苗开发者获得在全球市场上成功竞争所需的支持。
